|
93
|
309
|
4zseA |
Crystal structure of egfr 696-1022 t790m/v948r, crystal form ii |
|
100
|
303
|
5e8zA |
Tgf-beta receptor type 1 kinase domain (t204d) in complex with 3-amino-6-[4-(2-hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide |
|
73
|
304
|
5e7rA |
Crystal structure of tl10-81 bound to tak1-tab1 |
|
103
|
350
|
5ekoA |
Crystal structure of mapk13 complex with inhibitor |
|
83
|
289
|
5f20A |
Structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
|
76
|
262
|
4zs0A |
Human aurora a catalytic domain bound to sb-6-oh |
|
77
|
302
|
5ar8A |
Rip2 kinase catalytic domain (1 - 310) complex with biphenylsulfonamide |
|
100
|
302
|
5e8tA |
Tgf-beta receptor type 1 kinase domain (t204d) |
|
85
|
306
|
5ar4A |
Rip2 kinase catalytic domain (1 - 310) complex with sb-203580 |
|
78
|
286
|
5ap7A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
116
|
341
|
4zslA |
Mitogen activated protein kinase 7 in complex with inhibitor |
|
79
|
281
|
5ap1A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
79
|
273
|
5eolA |
Crystal structure of human pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor |
|
106
|
306
|
5e8uA |
Tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f,s280t, y282f,s287n,a350c,l352f) |
|
88
|
323
|
5em5A |
Egfr kinase domain mutant "tmlr" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
91
|
302
|
5e8yA |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) in complex with staurosporine |
|
77
|
267
|
5f4nA |
Multi-parameter lead optimization to give an oral chk1 inhibitor clinical candidate: (r)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (cct245737) |
|
88
|
290
|
5e1eA |
Human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution |
|
74
|
279
|
5ei2A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
103
|
355
|
5etcA |
Structure of inactive mapk14 with ordered activation loop |
|
92
|
309
|
5eg3A |
Crystal structure of the activated fgf receptor 2 (fgfr2) kinase domain in complex with the csh2 domain of phospholipase c gamma (plcgamma) |
|
86
|
305
|
5ar7A |
Rip2 kinase catalytic domain (1 - 310) complex with biaryl urea |
|
90
|
322
|
5edpA |
Egfr kinase (t790m/l858r) apo |
|
89
|
351
|
5etaA |
Structure of mapk14 with bound the kim domain of the toxoplasma protein gra24 |
|
72
|
280
|
5ap5A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
120
|
344
|
4zsjA |
Mitogen activated protein kinase 7 in complex with inhibitor |
|
99
|
304
|
5e8xA |
Tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f,s280t, y282f,s287n,a350c,l352f) in complex with staurosporine |
|
90
|
323
|
5em8A |
Egfr kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
103
|
303
|
5e90A |
Tgf-beta receptor type 1 kinase domain (t204d,i211v,y249f, s280t,y282f,s287n,a350c,l352f) in complex with 3-amino-6- [4-(2-hydroxyethyl)phenyl]-n-[4-(morpholin-4-yl)pyridin-3-yl]pyrazine-2-carboxamide |
|
112
|
356
|
4z9lA |
The structure of jnk3 in complex with an imidazole-pyrimidine inhibitor |
|
84
|
279
|
5ei6A |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
93
|
292
|
5f1zA |
Structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
|
72
|
282
|
5ehlA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
87
|
307
|
5ar5A |
Rip2 kinase catalytic domain (1 - 310) complex with benzimidazole |
|
86
|
322
|
5edqA |
Egfr kinase (t790m/l858r) with inhibitor compound 15: ~{n}-(7-chloranyl-1~{h}-indazol-3-yl)-7,7-dimethyl-2-(1~{h}-pyrazol-4-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
|
91
|
298
|
5ew3A |
Human vascular endothelial growth factor receptor 2 (kdr) kinase domain in complex with aal993 |
|
76
|
279
|
5ap3A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
97
|
291
|
5eobA |
Crystal structure of cmet in complex with novel inhibitor |
|
78
|
280
|
5ap0A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
|
121
|
347
|
4zsgA |
Mitogen activated protein kinase 7 in complex with inhibitor |
|
95
|
302
|
5e8vA |
Tgf-beta receptor type 2 kinase domain (e431a,r433a,e485a,k488a,r493a,r495a) |
|
102
|
301
|
5e8sA |
Tgf-beta receptor type 1 kinase domain (wt) |
|
87
|
324
|
5em7A |
Egfr kinase domain mutant "tmlr" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
92
|
302
|
5ew8A |
Fibroblast growth factor receptor 1 in complex with jnj-4275693 |
|
88
|
301
|
5e1sA |
The crystal structure of insr tyrosine kinase in complex with the inhibitor bi 885578 |
|
83
|
279
|
5ehoA |
Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (mps1) using a structure-based hydridization approach |
|
110
|
355
|
5etiA |
Structure of dead kinase mapk14 |
|
96
|
331
|
5efqA |
Crystal structure of human cdk13/cyclin k in complex with adp-aluminum fluoride |
|
87
|
305
|
5ar3A |
Rip2 kinase catalytic domain (1 - 310) complex with amp-pcp |
|
76
|
279
|
5ap2A |
Naturally occurring mutations in the mps1 gene predispose cells to kinase inhibitor drug resistance. |
